share_log

Goldman Sachs Maintains Buy on Calumet Specialty Prods, Lowers Price Target to $17

Benzinga ·  Oct 31, 2023 09:37

Goldman Sachs analyst Neil Mehta maintains Calumet Specialty Prods (NASDAQ:CLMT) with a Buy and lowers the price target from $19 to $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment